The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.
It is well established that human tumors overproduce plasmin a serine protease that is known to promote angiogenesis, tumor growth and metastasis. However, the mechanism by which endothelial or tumor cells regulate the proteolytic activity of plasmin is not well understood. Cell surface receptors regulate activation of plasminogen to plasmin and its proteolytic activity. Annexin II is one of the well studied receptors for plasminogen and tPA, which binds to plasminogen and converts it to plasmin. Plasmin is a highly reactive enzyme which is physiologically involved in fibrinolysis. Since the proteolytic activity of plasmin is very tightly regulated, uncontrolled production of plasmin can degrade extracellular matrix (ECM) and basement membrane (BM) of the surrounding blood vessels. Thus plasmin plays an important role in neoangiogenesis and cancer invasion and metastasis. Therefore, the receptor which regulates plasmin generation may be an attractive target for the development of anti-cancer/anti-metastatic agents. Angiostatin (AS), internal fragment of plasminogen, has been reported to inhibit human tumor growth and metastasis. We have shown that AS binds to endothelial/cancer cell surface annexin II with high affinity and interferes with plasmin generation suggesting that the role of plasmin/plasminogen system may be more complex than we previously thought. In this review we provide a comprehensive analysis of the literature in context of the role of annexin II in angiogenesis, tumor progression and metastasis. Compelling evidence from the literature and our own findings suggest that annexin II may be a potential target for the development of effective therapeutic strategies for the treatment of cancer and its induced metastasis.
Sharma
Mahesh C
MC
Department of Surgery, Drexel University College of Medicine, MS 413, 245 N 15th Street, Philadelphia, PA 19102, USA. ms66@drexel.edu
Sharma
Meena
M
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D043168:Angiostatins / Q000378:metabolism; D000818:Animals; D017306:Annexin A2 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018450:Disease Progression; D005109:Extracellular Matrix / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism*; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D010958:Plasminogen / Q000378:metabolism*; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D017306:Annexin A2; D000970:Antineoplastic Agents; D011956:Receptors, Cell Surface; D043168:Angiostatins; D010958:Plasminogen; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin